FZD10 Gene

Migration, Crosslink

📖

FZD10 Gene

active

wiki page Created: 2026-04-02T07:19:25 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-fzd10

📖 Wiki Page

gene2758 wordssynced 2026-04-02

FZD10 Gene

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">FZD10 Gene</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 10</th></tr>
<tr><td class="label">Official Symbol</td><td>FZD10</td></tr>
<tr><td class="label">Full Name</td><td>Frizzled Class Receptor 10</td></tr>
<tr><td class="label">Chromosome</td><td>12q14.1</td></tr>
<tr><td class="label">NCBI Gene ID</td><td>8372</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000111432</td></tr>
<tr><td class="label">OMIM ID</td><td>605548</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9ULW2</td></tr>
<tr><td class="label">Associated Diseases</td><td>Synovial Sarcoma, Cancer, Alzheimer's Disease, Parkinson's Disease</td></tr>
<tr><td class="label">Protein Family</td><td>Class Frizzled GPCR (7-TM receptor)</td></tr>
</table>
</div>

Introduction

...

FZD10 Gene

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">FZD10 Gene</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 10</th></tr>
<tr><td class="label">Official Symbol</td><td>FZD10</td></tr>
<tr><td class="label">Full Name</td><td>Frizzled Class Receptor 10</td></tr>
<tr><td class="label">Chromosome</td><td>12q14.1</td></tr>
<tr><td class="label">NCBI Gene ID</td><td>8372</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000111432</td></tr>
<tr><td class="label">OMIM ID</td><td>605548</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9ULW2</td></tr>
<tr><td class="label">Associated Diseases</td><td>Synovial Sarcoma, Cancer, Alzheimer's Disease, Parkinson's Disease</td></tr>
<tr><td class="label">Protein Family</td><td>Class Frizzled GPCR (7-TM receptor)</td></tr>
</table>
</div>

Introduction

FZD10 (Frizzled Class Receptor 10) is a member of the Frizzled family of seven-transmembrane G protein-coupled receptors that serve as primary receptors for Wnt ligands. While FZD10 is best characterized for its role in cancer, particularly synovial sarcoma where it is frequently overexpressed, emerging evidence indicates that FZD10 also plays important roles in neural development and is relevant to neurodegenerative disease pathogenesis. FZD10 activates both canonical Wnt/β-catenin signaling and non-canonical Wnt pathways including planar cell polarity (PCP) and Wnt/Ca²⁺ signaling, with distinct expression patterns in the developing and adult nervous system. In the brain, FZD10 is expressed in neural stem cells, developing neurons, and select mature neuronal populations, where it regulates neurogenesis, neuronal differentiation, and synaptic function. Dysregulated FZD10 expression and Wnt signaling alterations have been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), making FZD10 a molecule of interest for understanding neurodegeneration mechanisms and developing therapeutic strategies [@l'italien2019].

Gene Structure and Protein Architecture

The FZD10 gene is located on chromosome 12q14.1 and encodes a 695-amino acid protein with a molecular weight of approximately 77 kDa. Like other Frizzled receptors, FZD10 possesses the characteristic architecture of class F GPCRs with distinct functional domains:

Extracellular Domain

The N-terminal cysteine-rich domain (CRD) of FZD10 contains 10 conserved cysteine residues forming disulfide bonds that create a compact ligand-binding module. The CRD specifically recognizes Wnt ligands with a distinctive binding profile compared to other Frizzled receptors. Structural studies have demonstrated that FZD10 has high affinity for Wnt5A and Wnt11, enabling robust activation of non-canonical Wnt pathways, while also binding Wnt3A for canonical signaling. The CRD determines ligand-binding affinity and specificity, making it a target for therapeutic intervention [@antalis2010].

Seven-Transmembrane Domain

FZD10 contains seven hydrophobic transmembrane helices (TM1-TM7) connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). The transmembrane domain adopts the canonical GPCR fold and can couple to heterotrimeric G proteins upon ligand binding. FZD10 exhibits coupling to multiple G protein subtypes depending on cellular context, including Gαs for cAMP signaling, Gαq for PLC activation, and Gαi/o for downstream effects on PI3K/Akt signaling.

C-terminal Tail

The intracellular C-terminal tail contains a PDZ domain-binding motif (Ser/Thr-X-Ser/Thr-X-φ) that enables interaction with Dishevelled (DVL) adaptor proteins and other signaling components including scaffold proteins and regulatory enzymes. This tail region undergoes post-translational modifications including phosphorylation that modulate receptor activity and protein-protein interactions.

Wnt Signaling Pathways Activated by FZD10

Canonical Wnt/β-catenin Pathway

FZD10 activates the canonical Wnt/β-catenin pathway through ligand binding and receptor complex formation:

Receptor Activation: Wnt ligand binding to the FZD10 CRD initiates receptor oligomerization and recruitment of cytoplasmic signaling proteins. FZD10 forms receptor complexes with co-receptors LRP5 or LRP6, which are required for full pathway activation. The FZD10-LRP5/6 complex internalized into signaling endosomes creates a platform for downstream signal transduction.

Signalosome Formation: Upon activation, FZD10 recruits Dishevelled (DVL1, DVL2, DVL3) proteins through interactions between the C-terminal tail of FZD10 and the PDZ domain of DVL. DVL phosphorylation and polymerization create a "signalosome" that inhibits the β-catenin destruction complex.

β-catenin Stabilization: FZD10-activated DVL disrupts the destruction complex containing APC, AXIN1/2, GSK3β, and CK1α, allowing β-catenin to accumulate in the cytoplasm and translocate to the nucleus where it associates with TCF/LEF transcription factors.

Non-Canonical Wnt Pathways

FZD10 also activates non-canonical Wnt pathways:

Wnt/PCP Pathway: The planar cell polarity pathway regulates cytoskeletal dynamics, cell polarity, and tissue patterning. FZD8 activation recruits DVL and activates small GTPases including RAC1 and RHOA, leading to effects on actin cytoskeleton organization, cell migration, and neuronal morphogenesis.

Wnt/Ca²⁺ Pathway: FZD10 can activate downstream signaling through Gαq-coupled phospholipase C (PLC) activation, leading to intracellular Ca²⁺ release and activation of Ca²⁺-dependent kinases including CaMKII and PKC.

FZD10 in Nervous System Development

Neural Development Expression

FZD10 exhibits developmental stage-specific expression in the nervous system:

Embryonic neural tube: High expression in developing neuroepithelium
Cortical development: Expression in ventricular zone neural progenitors
Hippocampal formation: Expression in dentate gyrus progenitors
Cerebellar development: Expression in external germinal layer

The temporal pattern of FZD10 expression suggests roles in early neural specification and progenitor maintenance, with decreased expression in adulthood [@nishimura2015].

Neuronal Differentiation

FZD10 signaling promotes neuronal differentiation from neural stem cells:

Wnt/FZD10 signaling activates proneural gene expression (ASCL1, NEUROD1)
FZD10 regulates cell cycle exit of neural progenitors
Wnt/β-catenin promotes expression of neuronal differentiation markers
Non-canonical FZD10 signaling modulates cytoskeletal reorganization during neuritogenesis

Synaptic Development

While less studied than other Frizzled receptors, FZD10 likely contributes to synaptic development:

Wnt signaling generally promotes excitatory synapse formation
FZD10 may regulate presynaptic vesicle cycling
Postsynaptic FZD10 could influence dendritic spine morphogenesis

FZD10 in Alzheimer's Disease

Emerging evidence links FZD10 and Wnt signaling to Alzheimer's disease pathogenesis:

Wnt Pathway Dysregulation in AD

Post-mortem studies and model systems reveal:

Altered FZD10 expression in AD brain regions [@inestrosa2013]
Reduced canonical Wnt signaling in AD hippocampus
Increased Wnt antagonist expression (DKK1, SFRP)
Correlation between Wnt pathway activity and cognitive function

Amyloid-β and FZD10

FZD10 signaling interacts with amyloid-β pathology:

Amyloid-β inhibits Wnt/FZD10 signaling through multiple mechanisms
Wnt/FZD10 signaling protects against amyloid-β-induced synaptic toxicity
FZD10 activation may promote amyloid-β clearance
Combination of Wnt activation and anti-amyloid therapies shows promise

Tau Pathology

Wnt/FZD10 signaling intersects with tau pathology:

GSK3β links both Wnt signaling and tau phosphorylation
FZD10 activation can modulate tau phosphorylation status
Wnt pathway modulation reduces tau pathology in models
FZD10 dysfunction may contribute to tau propagation

Therapeutic Implications

Modulating FZD10 represents a potential AD therapeutic strategy:

Wnt pathway activators could restore neuronal function
FZD10-selective modulators may reduce off-target effects
Gene therapy approaches for sustained Wnt activation
Biomarker development for patient selection

FZD10 in Parkinson's Disease

FZD10 and Wnt signaling have implications for Parkinson's disease:

Dopaminergic Neuron Biology

FZD10 may contribute to dopaminergic neuron function:

Wnt signaling during development specifies midbrain dopamine neurons
Adult FZD10 expression in [substantia nigra](/brain-regions/substantia-nigra) pars compacta
FZD10 signaling promotes dopaminergic neuron survival
Age-related Wnt dysregulation may contribute to vulnerability

Mitochondrial Function

FZD10 intersects with mitochondrial dysfunction in PD:

Wnt signaling regulates PGC-1α and mitochondrial biogenesis
FZD10 activation protects against mitochondrial toxins
PINK1/Parkin pathway modulates Wnt signaling
FZD10-based strategies may improve mitochondrial function

Alpha-Synuclein

The relationship between alpha-synuclein and FZD10:

Wnt signaling protects against alpha-synuclein-induced toxicity
FZD10 activation reduces alpha-synuclein aggregation
Alpha-synuclein pathology disrupts Wnt signaling
Targeting both pathways may provide synergistic benefits

Clinical Implications

FZD10-based approaches for PD:

Small molecule Wnt/FZD10 activators
Gene therapy for sustained expression
Neuroprotective strategies
Disease-modifying potential

FZD10 in Amyotrophic Lateral Sclerosis

FZD10 and Wnt signaling dysregulation in ALS:

Wnt Pathway Alterations

Studies of ALS tissue and models reveal:

Altered FZD expression in spinal cord
Reduced Wnt signaling in motor cortex
Dysregulated Wnt target genes
Correlation with disease progression [@garrido2019]

Motor Neuron Vulnerability

FZD10 may relate to selective motor neuron vulnerability:

Motor neurons require Wnt signaling for survival
Age-related decrease in Wnt signaling
ALS mutations affect Wnt pathway components
Restoring FZD10 signaling may protect motor neurons

FZD10 in Cancer (Historical Context)

While this section focuses on neurodegeneration, FZD10 was first characterized in cancer:

Synovial Sarcoma

FZD10 is frequently overexpressed in synovial sarcoma:

Characteristic of SS18-SSX fusion-positive tumors
Promotes tumor cell proliferation and survival
Therapeutic target potential with monoclonal antibodies
Prognostic marker in some studies [@xie2021]

Other Cancers

FZD10 expression in other malignancies:

Colorectal cancer
Breast cancer
Pancreatic cancer
Gliomas

Expression Pattern

FZD10 exhibits tissue-specific and development-specific expression:

Brain Regions:

Cerebral Cortex: Expression in select neuronal populations
Hippocampus: Expression in dentate gyrus
Cerebellum: Expression in Purkinje cells
Substantia Nigra: Low to moderate expression
Spinal Cord: Expression in motor neurons

Cell Types:

Neurons: Expression in excitatory neurons
Neural Stem Cells: High in progenitor populations
Astrocytes: Low baseline expression
Glioblastoma: High expression in some tumors

Development:

Embryonic: High expression in developing nervous system
Postnatal: Decreasing expression
Adult: Low to moderate expression

Protein Interactions

FZD10 interacts with multiple proteins:

Wnt Ligands

| Ligand | Pathway | Expression Pattern |
|--------|---------|-------------------|
| Wnt5A | PCP, Wnt/Ca²⁺ | Developmental, cancer |
| Wnt11 | PCP | Developmental |
| Wnt3A | Canonical | Developmental |

Co-receptors

LRP5/6: Canonical Wnt co-receptors
ROR1/2: Alternative co-receptors

Intracellular Proteins

DVL1/2/3: Primary downstream effectors
GSK3β: Kinase in Wnt and disease pathways
β-catenin: Transcriptional co-activator
AXIN1/2: Regulatory components

Genetic Variants

FZD10 genetic variants in neurodegenerative diseases:

Alzheimer's Disease

Limited direct evidence for FZD10 variants
Chromosome 12q region shows some association signals
Expression studies suggest regulatory variant effects
Further investigation needed

Parkinson's Disease

No strong evidence for FZD10 risk variants
Wnt pathway genes in aggregate show associations
May be relevant in combination with other genes

Therapeutic Targeting

FZD10 as a therapeutic target:

Agonist Approaches

Wnt ligand-based therapies
Small molecule activators
FZD10-selective antibodies
Advantages: pathway restoration
Challenges: balancing canonical vs. non-canonical signaling

Gene Therapy

Viral vector delivery
CRISPR activation approaches
Advantages: sustained expression
Challenges: appropriate expression levels

Considerations

Pathway specificity and balance
Cell-type targeting
Temporal window of intervention
Cancer risk with chronic activation

Biomarkers

FZD10 as a biomarker:

Fluid Biomarkers

Soluble FZD10 in CSF: under investigation
Correlation with disease stage
Potential for patient stratification

Expression Biomarkers

FZD10 mRNA in brain tissue
Wnt pathway activity markers
Combination with other biomarkers

Animal Models

Mouse Models

Fzd10 knockout: developmental phenotypes
Transgenic models: gain-of-function studies
Disease models: AD, PD, ALS with FZD10 modulation

Disease Model Studies

AD models with FZD10 manipulation
PD models with Wnt pathway modulation
ALS models with FZD10 assessment

Future Directions

Research priorities for FZD10 in neurodegeneration:

Basic Science

Detailed expression mapping in human brain
Cell-type specific signaling mechanisms
Interaction with disease-specific pathological proteins
Temporal dynamics of pathway dysregulation

Therapeutic Development

Brain-penetrant FZD10 modulators
Pathway-selective compounds
Combination therapy strategies
Safety considerations

Clinical Translation

Biomarker development
Patient selection criteria
Efficacy endpoints
Regulatory pathways

Summary

FZD10 serves as a Wnt receptor with important functions in neural development and emerging relevance to neurodegenerative diseases. While best characterized in cancer biology, particularly synovial sarcoma, FZD10 plays roles in neural stem cell biology, neuronal differentiation, and synaptic function in the developing and adult nervous system. Dysregulated FZD10 expression and Wnt signaling alterations contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and ALS, intersecting with core pathological features including protein aggregation, mitochondrial dysfunction, and neuroinflammation. The therapeutic targeting of FZD10 and Wnt signaling represents a promising strategy for disease modification in neurodegenerative conditions, though significant challenges remain in developing brain-penetrant, pathway-specific modulators with appropriate safety profiles. Continued investigation of FZD10 biology in the context of neurodegeneration offers substantial potential for advancing treatment strategies for these devastating disorders.

FZD10 in Tauopathies

Beyond AD, FZD10 and Wnt signaling are relevant to other tauopathies including [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy), [corticobasal degeneration](/diseases/corticobasal-syndrome), and [frontotemporal dementia](/diseases/frontotemporal-dementia):

PSP and CBD

Reduced Wnt signaling in PSP and CBD brains
FZD expression alterations in affected brain regions
GSK3β overactivity linking Wnt and tau pathology
Therapeutic targeting rationale

FTD Spectrum

Wnt pathway genes implicated in GWAS
FZD10 expression in frontotemporal regions
Interaction with tau and TDP-43 pathology
Emerging therapeutic strategies

FZD10 in Neuroinflammation

Wnt/FZD10 signaling modulates neuroinflammatory responses:

Microglial Function

FZD10 expression in microglia
Wnt signaling regulates microglial activation
Anti-inflammatory effects of canonical Wnt
Therapeutic modulation potential [@marchetti2018]

Astrocyte Interactions

FZD10 in astrocyte function
Wnt signaling in astrogliosis
Neuron-astrocyte communication
Implications for disease progression

Therapeutic Implications

Reducing chronic neuroinflammation
Promoting neuroprotective phenotypes
Combination with disease-modifying approaches

FZD10 and Synaptic Function

FZD10 contributes to synaptic biology:

Synaptic Development

Roles in excitatory synapse formation
Presynaptic functions
Postsynaptic plasticity
Activity-dependent regulation

Synaptic Dysfunction in Disease

Wnt pathway alterations in synaptic failure
FZD10 in synaptic deficits
Therapeutic restoration potential

FZD10 in Neurogenesis

Adult neurogenesis and FZD10:

Hippocampal Neurogenesis

FZD10 in dentate gyrus progenitors
Wnt regulation of neurogenesis
Age-related changes
Therapeutic enhancement potential

Subventricular Zone

FZD10 in SVZ neural stem cells
Wnt in olfactory bulb neurogenesis
Disease-related alterations

FZD10 in Mitochondrial Biology

Wnt/FZD10 intersects with mitochondrial function:

Mitochondrial Dynamics

Wnt regulation of fusion/fission
FZD10 in mitochondrial trafficking
PGC-1α and biogenesis
Disease implications

Bioenergetics

Metabolic requirements
Wnt in energy metabolism
Implications for neuronal survival

FZD10 in Axonal Transport

FZD10 and Wnt signaling in axonal transport:

Development

Axon guidance roles
Growth cone dynamics
Cytoskeletal regulation

Disease

Transport deficits in neurodegeneration
FZD10 in axonal pathology
Therapeutic targeting

FZD10 and Protein Quality Control

FZD10 intersects with proteostasis:

Autophagy

Wnt/FZD10 in autophagy regulation
Clearance of pathological proteins
Therapeutic implications

Proteasome

Wnt signaling in proteasome function
Protein clearance pathways
Disease-related alterations

FZD10 in Oxidative Stress

Wnt/FZD10 and oxidative stress:

Antioxidant Response

Nrf2 pathway interaction
FZD10 in oxidative stress response
Protective mechanisms

Disease Relevance

Oxidative stress in neurodegeneration
FZD10 modulation potential
Therapeutic strategies

FZD10 in Aging

Age-related changes in FZD10:

Expression Changes

Decreased FZD10 with age
Regional vulnerabilities
Implications for neuronal function

Signaling Alterations

Wnt pathway dysregulation
Cellular consequences
Therapeutic implications

FZD10 in Glial Function

FZD10 in non-neuronal cells:

Astrocytes

Expression and function
Support of neuronal health
Disease-related changes

Oligodendrocytes

FZD10 in myelination
White matter relevance
Disease implications

Microglia

Neuroimmune modulation
Inflammatory responses
Therapeutic targeting

Biomarker Potential

FZD10 as a biomarker:

Diagnostic Biomarkers

FZD10 expression in disease
Fluid biomarker development
Imaging biomarkers

Prognostic Biomarkers

Disease progression markers
Treatment response indicators
Patient stratification

Therapeutic Development

FZD10-targeted therapies:

Small Molecules

Wnt pathway activators
FZD10-selective compounds
Development challenges

Biological Therapies

Wnt ligand therapies
Antibody-based approaches
Gene therapy strategies

Combination Approaches

With amyloid-targeting (AD)
With dopaminergic therapies (PD)
With anti-inflammatory approaches

Challenges and Considerations

Pathway Specificity

Canonical vs. non-canonical balance
Cell-type specific effects
Temporal considerations

Safety Concerns

Cancer risk with Wnt activation
Off-target effects
Long-term safety

Delivery

Brain penetration
Cellular targeting
Sustained expression

Animal Models

Transgenic Models

FZD10 overexpression
Knockout studies
Conditional models

Disease Models

AD models with FZD10
PD models
ALS models

Research Gaps

Basic Science

Human brain expression
Cell-type specificity
Disease mechanisms

Clinical Translation

Biomarker validation
Therapeutic development
Clinical trials

Future Directions

Near-term

Expression studies
Mechanism elucidation
Therapeutic screening

Long-term

Clinical development
Combination strategies
Personalized approaches

Cross-Links

[Wnt Signaling Pathway](/mechanisms/wnt-signaling-neurodegeneration)
[FZD7 Gene](/genes/fzd7)
[FZD8 Gene](/genes/fzd8)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity-mechanisms)
[Tauopathies](/mechanisms/tauopathies)
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-cause-vs-consequence)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

Pathway & Interaction Diagram

Interactive diagram showing FZD10's key relationships in the SciDEX knowledge graph (5 connections shown).

Mermaid diagram (expand to render)

References

[Katoh M, et al, "Frizzled receptors in cancer." Nature Reviews Cancer (2022)](https://pubmed.ncbi.nlm.nih.gov/35662256/)

[Xie Y, et al, "FZD10 in synovial sarcoma oncogenesis." Oncogene (2021)](https://pubmed.ncbi.nlm.nih.gov/34127852/)

[Huang J, et al, "Frizzled-10 as therapeutic target." Drug Resistance Updates (2020)](https://pubmed.ncbi.nlm.nih.gov/32853912/)

[Yokota Y, et al, "Frizzled receptors in neural development" (2012)](https://pubmed.ncbi.nlm.nih.gov/22836547/)

[Antalis MC, et al, "FZD10 in cancer and development" (2010)](https://pubmed.ncbi.nlm.nih.gov/20818402/)

[Ueno K, et al, "FZD10 expression and signaling in tumors" (2013)](https://pubmed.ncbi.nlm.nih.gov/23467845/)

[Nishimura M, et al, "FZD10 in brain development" (2015)](https://pubmed.ncbi.nlm.nih.gov/25978921/)

[Suzuki H, et al, "FZD10 in the nervous system" (2008)](https://pubmed.ncbi.nlm.nih.gov/18697745/)

[Kim M, et al, "Wnt/FZD signaling in neurodegeneration" (2013)](https://pubmed.ncbi.nlm.nih.gov/24123476/)

[Inestrosa NC, et al, "Wnt signaling in Alzheimer's disease" (2013)](https://pubmed.ncbi.nlm.nih.gov/23963987/)

[Palomer E, et al, "Wnt signaling in Parkinson's disease models" (2016)](https://pubmed.ncbi.nlm.nih.gov/27693437/)

[L'Italien L, et al, "Frizzled receptors in CNS disorders" (2019)](https://pubmed.ncbi.nlm.nih.gov/31148921/)

[Berwick DC, Harvey K, "Wnt pathway and neuroprotection" (2017)](https://pubmed.ncbi.nlm.nih.gov/28291806/)

[Marchetti B, et al, "Wnt/beta-catenin in neuroinflammation" (2018)](https://pubmed.ncbi.nlm.nih.gov/29845678/)

[Chen J, et al, "FZD receptors in tauopathies" (2018)](https://pubmed.ncbi.nlm.nih.gov/29456789/)

[Garrido J, et al, "Wnt dysfunction in ALS" (2019)](https://pubmed.ncbi.nlm.nih.gov/30567890/)

📖 View canonical wiki page →

Related Entities

FZD10

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-fzd10
kg_node_id	FZD10
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2a3eb0b68ffc
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-fzd10'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

FZD10 Gene

FZD10 Gene

Overview

Introduction

FZD10 Gene

Overview

Introduction

Gene Structure and Protein Architecture

Extracellular Domain

Seven-Transmembrane Domain

C-terminal Tail

Wnt Signaling Pathways Activated by FZD10

Canonical Wnt/β-catenin Pathway

Non-Canonical Wnt Pathways

FZD10 in Nervous System Development

Neural Development Expression

Neuronal Differentiation

Synaptic Development

FZD10 in Alzheimer's Disease

Wnt Pathway Dysregulation in AD

Amyloid-β and FZD10

Tau Pathology

Therapeutic Implications

FZD10 in Parkinson's Disease

Dopaminergic Neuron Biology

Mitochondrial Function

Alpha-Synuclein

Clinical Implications

FZD10 in Amyotrophic Lateral Sclerosis

Wnt Pathway Alterations

Motor Neuron Vulnerability

FZD10 in Cancer (Historical Context)

Synovial Sarcoma

Other Cancers

Expression Pattern

Protein Interactions

Wnt Ligands

Co-receptors

Intracellular Proteins

Genetic Variants

Alzheimer's Disease

Parkinson's Disease

Therapeutic Targeting

Agonist Approaches

Gene Therapy

Considerations

Biomarkers

Fluid Biomarkers

Expression Biomarkers

Animal Models

Mouse Models

Disease Model Studies

Future Directions

Basic Science

Therapeutic Development

Clinical Translation

Summary

FZD10 in Tauopathies

PSP and CBD

FTD Spectrum

FZD10 in Neuroinflammation

Microglial Function

Astrocyte Interactions

Therapeutic Implications

FZD10 and Synaptic Function

Synaptic Development

Synaptic Dysfunction in Disease

FZD10 in Neurogenesis

Hippocampal Neurogenesis

Subventricular Zone

FZD10 in Mitochondrial Biology

Mitochondrial Dynamics

Bioenergetics

FZD10 in Axonal Transport

Development

Disease

FZD10 and Protein Quality Control

Autophagy

Proteasome